Abstract

In pet cancer diagnostics, there is a dire need for molecular diagnostic tools that give results in few hours rather than days. Hematopoietic cancers, particularly lymphoma, the most common type of hematopoietic cancer, have been reported in dogs. Diagnosis of blood malignancies is difficult based on histological and cytological examination. In such a situation, advanced molecular techniques may be helpful to confirm a diagnosis. It is very much essential to diagnose blood malignancies. In the present study, 123 blood samples from dogs were screened to diagnose the lymphoma using polymerase chain reaction for antigen receptor rearrangement and 10 blood samples were screened to diagnose chronic myeloid leukemia using a two-step nested polymerase chain reaction for detection of the bcr-abl fusion. Twenty one tissue samples from abnormal growth on the body surface of dogs were screened to diagnose mast cell tumor using polymerase chain reaction for detection of mutation at juxtamembrane domain of c-kit gene. Two out of 123 dogs were found to be positive for T-cell lymphoma, 3 dogs were positive for chronic myeloid leukemia out of 10 samples and 1 tissue sample was found to be positive for mast cell tumor out of 21 suspected samples. Thus, regular use of molecular diagnostics in veterinary practice for speedy and early diagnosis of tumors, particularly insidious neoplastic conditions, as well as in taking therapeutic decisions is very crucial.

Reference

Birren B, Green ED, Klapholz S, Myers RM and Roskams J, 1997. Genomic analysis a laboratory manual. USA: Cold Spring Harbor Lab

Breen M and Modiano JF, 2008. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans–man and his best friend share more than companionship. J Chromosome Res, 16(1): 145-154, doi: 10.1007/s10577-007-1212-4

Burnett RC, Vernau W, Modiasno JF, Olver CS, Moore PF et al., 2003. Diagnosis of canine lymphoid neoplasia using clonal rearrangement of antigen receptor genes. Vet Pathol, 40(1): 32-41, doi: 10.1354/vp.40-1-32

Cameron LJ, Grahn, RA, Chien MB, Lyons LA and London CA, 2004. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest, 16(2): 95-100, doi: 10.1177/104063870401600201

Cardoso HJ, Figueira MI and Socorro S, 2017. The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer. J Cell Commun Signal, 11(4): 297-307, doi: 10.1007/s12079-017-0399-1

Carter RF and Valli VE, 1988. Advances in the cytologic diagnosis of canine lymphoma. Semin Vet Med Surg Small Anim, 3(2): 167-175

Chen YC, Liao JW, Hsu WL, Hsu WL and Chang SC, 2016. Identification of the two KIT isoforms and their expression status in canine hemangiosarcomas. BMC Vet Res, 12(1): 142, doi: 10.1186/s12917-016-0772-y    

Cozzolino I, Rocco M, Villani G and Picardi M, 2016. Lymph node fine-needle cytology of non-Hodgkin lymphoma: diagnosis and classification by flow cytometry. Acta Cytol, 60(4): 302-314, doi: 10.1159/000448389

Downing S, Chien MB, Kass PH, Moore PF and London CA, 2002. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res, 63: 1718-1723, doi: 10.2460/ajvr.2002.63.1718

Fischer AH, Jacobson KA, Rose J and Zeller R, 2008. Hematoxylin and eosin staining of tissue and cell sections. Cold Spring Harb. Protoc, 5: 4986, doi: 10.1101/pdb.prot4986

Galli SJ, Zsebo KM and Geissler EN, 1994. The kit ligand, stem cell factor. Adv Immunol, 55: 1-95, doi: 10.1016/s0065-2776(08)60508-8

Gentilini F, Calzolari C, Turba ME, Bettini G, Famigli BP, 2009. Gene scanning analysis of Ig/TCR gene rearrangements to detect clonality in canine lymphomas. Vet Immunol Immunopathol, 127(1-2): 47-56, doi: 10.1016/j.vetimm.2008.09.014

Ma Y, Longley BJ, Wang X, Blount JL, Langley K et al., 1999. Clustering of activating mutations in c-KIT’s juxtamembrane coding region in canine mast cell neoplasms. J Investig Dermatol, 112(2): 165-170, doi: 10.1046/j.1523-1747.1999.00488.x

Marino CL, Tran JN and Stokol T, 2017. Atypical chronic myeloid leukemia in a German Shepherd dog.  J Vet Diagn Invest, 29(3): 338-345, doi: 10.1177/1040638716689581

Nocka K, Buck J, Levi E and Besmer P, 1990. Candidate ligand for the C-kit transmembrane kinase receptor: KL, a ?broblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J, 9(10): 3287-3294, doi: 10.1002/j.1460-2075.1990.tb07528.x

Radich JP, Gooley T, Bryant E, Chauncey T, Clift R et al., 2001. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late” 18 months or more after transplantation. Blood, 98(6): 1701-1707, doi: 10.1182/blood.v98.6.1701

Selvarajah GT, Bonestroo FA, Sprang EPT, Kirpensteijn J and Mol JA, 2017. Reference gene validation for gene expression normalization in canine osteosarcoma: A geNorm algorithm approach. BMC Vet Res, 13(1): 354-362, doi: 10.1186/s12917-017-1281-3   

Tsujimura T, Morii E, Nozaki M, Hashimoto K, Moriyama Y et al., 1996. Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice. Blood, 88(4): 1225-1233

Vail DM and Withrow SJ, 2007. Small Animal Clinical Oncology, 4th edn. Saunders Elsevier, St. Louis, Mo

Waugh EM, Gallagher A, Haining H, Johnston PEJ, Marchesi F et al., 2016. Optimisation and validation of a PCR for antigen receptor rearrangement (PARR) assay to detect clonality in canine lymphoid malignancies. Vet Immunol Immunopathol, 182: 115-124, doi: 10.1016/j.vetimm.2016.10.008

Zemke D, Yamini B and Yuzbasiyan GV, 2002. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol, 39(5): 529-535, doi: 10.1354/vp.39-5-529